Program

08:59 a.m. - 10:30 a.m.

Johannes Vermeer and Frans van Mieris

S1 Scientific Collaborations: Horizon2020 CURE UM

Moderators: Niels Brouwer (The Netherlands), Martyna Elas (Poland), B. Ewa Jagalska (The Netherlands) & Sergio Roman-Roman (France)

08:59 a.m. - 09:00 a.m.

Introducing CURE UM

Presenter: Sergio Roman-Roman (France)

09:00 a.m. - 09:08 a.m.

Protein tyrosine kinase activity in primary uveal melanoma is associated with the presence of tumour-infiltrating leukocytes

Presenter: Annemijn Wierenga (The Netherlands)

09:08 a.m. - 09:16 a.m.

Novel therapies for uveal melanoma

Presenter: Kseniya Glinkina (The Netherlands)

09:16 a.m. - 09:24 a.m.

Tumor-infiltrating T cells can successfully be expanded from primary uveal melanoma after separation from their tumor environment

Presenter: Gülcin Gezgin (The Netherlands)

09:24 a.m. - 09:32 a.m.

Characterization of immune cell infiltrates and immune checkpoints in primary UM and liver metastases

Presenter: Raymond Barnhill (France)

09:32 a.m. - 09:40 a.m.

The high-risk replacement histopathologic growth pattern in UM liver metastases

Presenter: Raymond Barnhill (France)

09:40 a.m. - 09:48 a.m.

Tumour pigmentation and chromosome 3 are related in uveal melanoma

Presenter: Maria Chiara Gelmi (The Netherlands)

09:48 a.m. - 09:56 a.m.

Ferroptosis inhibition by melanin promotes metastatic colonization of melanoma cells

Presenter: B. Ewa Jagalska (The Netherlands)

09:56 a.m. - 10:04 a.m.

Melanization of human UM tumors affects their metastasizing in mice

Presenter: Małgorzata Szczygieł (Poland)

10:04 a.m. - 10:12 a.m.

Uveal melanoma cell lines grown as 3D tumor spheroids

Presenter: Anna Kozińska (Poland)

10:12 a.m. - 10:20 a.m.

Vitreous fluid as a novel liquid biopsy for primary uveal melanoma

Presenter: Rogier J. Nell (The Netherlands)

10:20 a.m. - 10:28 a.m.

Ocular toxicity in uveal melanoma patients treated in the first year of a new proton therapy center

Presenter: Marina Marinkovic (The Netherlands)

10:30 a.m. - 11:00 a.m.

Coffee break

11:00 a.m. - 12:30 p.m.

Johannes Vermeer and Frans van Mieris

S2 International Collaborations in Ocular Oncology

Moderators: Rana'a Al Jamal (Finland), Brenda Gallie (Canada), Rogier J. Nell (The Netherlands) & Vicktoria (vicky) Vishnevskia-Dai (Israel)

11:00 a.m. - 11:08 a.m.

PRIMA (PRegnancy In uveal Melanoma Analysis) study ‎- A European OOG MultiCenter study

Presenter: Shahar Frenkel (Israel)

11:08 a.m. - 11:16 a.m.

Clinical phenotype of germline BAP1 mutation mmong pediatric uveal melanomas

Presenter: Rana'a Al Jamal (Finland)

11:16 a.m. - 11:24 a.m.

Nevus of Ota: Suggestion for new ocular classification

Presenter: Vicktoria (vicky) Vishnevskia-Dai (Israel)

11:24 a.m. - 11:32 a.m.

Capturing uveal melanoma (UM) global practice patterns and clinical outcomes in the collaborative ocular melanoma natural history (OMNi; NCT04588662) study

Presenter: Richard Carvajal (United States)

11:32 a.m. - 11:40 a.m.

Euracan collaboration

Presenters: Ellen Kapiteijn (The Netherlands) & Sophie Piperno-Neumann (France)

11:40 a.m. - 11:48 a.m.

An integrative, prospective clinical and tissue database for uveal melanoma

Presenter: Lauren Dalvin (United States)

11:48 a.m. - 11:56 a.m.

VISION (Virtual Information System to Improve Outcomes and Networks) - Advancing Ocular Melanoma (OM) research through patient powered data collection

Presenter: Sara Selig (United States)

11:56 a.m. - 12:04 p.m.

Developing an ocular oncology fellowship program

Presenter: Hatem Krema (Canada)

12:04 p.m. - 12:12 p.m.

Stage IV uveal melanoma: Pooled data from of an international registry

Presenter: Gaurav Garg (India)

12:12 p.m. - 12:20 p.m.

Update on international Rb database

Presenter: Brenda Gallie (Canada)

12:20 p.m. - 12:28 p.m.

High-level MYCN-amplified RB1-proficient retinoblastoma tumors retain distinct molecular signatures

Presenter: Josephine Dorsman (The Netherlands)

EURbG Business Meeting

11:00 a.m. - 12:30 p.m.

Willem van de Velde

Rb FAM (parallel session, members only)

12:30 p.m. - 01:30 p.m.

Lunch break

01:30 p.m. - 02:00 p.m.

Johannes Vermeer and Frans van Mieris

S3 Lex van der Eb Lecture

01:30 p.m. - 01:40 p.m.

Development Leiden Bio Science Park

Presenter: Bart van Zijll Langhout (The Netherlands)

01:40 p.m. - 02:00 p.m.

Lex van der Eb Lecture

Presenter: J. William Harbour (United States)

Moderator: Martine Jager (The Netherlands)

EURbG Business Meeting

01:30 p.m. - 03:30 p.m.

Willem van de Velde

EURbG Business Meeting (parallel session, members only)

02:00 p.m. - 03:30 p.m.

Johannes Vermeer and Frans van Mieris

S4 Genetics and Epigenetics in Oncology

Moderators: Shahar Frenkel (Israel), J. William Harbour (United States), Emine Kiliç (The Netherlands) & Marc-Henri Stern (France)

02:00 p.m. - 02:10 p.m.

Aging and epigenetic changes

Presenter: Bruce Ksander (United States)

02:10 p.m. - 02:18 p.m.

Genetics and prognostic value of TERT promoter mutations in conjunctival melanoma

Presenter: Natasha van Poppelen (The Netherlands)

02:18 p.m. - 02:26 p.m.

Contribution of MYC copy number gain and mutations in tumor suppressor genes to the oncogenesis of ocular adnexal sebaceous carcinomas

Presenter: Cornelia Peterson (United States)

02:26 p.m. - 02:34 p.m.

Primary UM display intratumoral heterogeneity; HES6, a driver of metastatic disease

Presenter: Corine Bertolotto (France)

02:34 p.m. - 02:42 p.m.

Disease-specific mortality among patients with local recurrence from uveal melanoma is primarily driven by chromosomes 3 and 8q

Presenter: Mette Bagger (Denmark)

02:42 p.m. - 02:50 p.m.

Chromosome 3 and 8q aberrations in uveal melanoma show greater impact on survival in patients with light iris versus dark iris color

Presenter: Martine Jager (The Netherlands)

02:50 p.m. - 02:58 p.m.

Different pigmentation risk loci for high-risk, monosomy 3 and low-risk, disomy 3 uveal melanomas

Presenter: Marc-Henri Stern (France)

02:58 p.m. - 03:06 p.m.

Impact of PRAME status on Gene Expression Profile to predict metastasis in UM: interim analysis of the COOG2

Presenter: Alison Skalet (United States)

03:06 p.m. - 03:14 p.m.

Leveraging single cell genomics and epigenomics to provide accurate prognostication for patients with uveal melanoma

Presenter: Mathieu Bakhoum (United States)

03:14 p.m. - 03:22 p.m.

Aqueous humor-derived MYD88 L265P mutation analysis in vitreoretinal lymphoma: A potential less-invasive method for diagnosis and treatment response assessment

Presenter: Hakan Demirci (United States)

03:22 p.m. - 03:30 p.m.

Ocular adnexal large B-cell lymphoma: Prevalence and prognostic value of MYD88 and CD79B mutations, double-hit lymphoma, and double-expressor phenotype

Presenter: Marina Knudsen Kirkegaard (Denmark)

03:30 p.m. - 04:00 p.m.

Coffee break

04:00 p.m. - 05:00 p.m.

Johannes Vermeer and Frans van Mieris

S5 Immunology in Ocular Oncology

Moderators: Marlana Orloff (United States), Sophie Piperno-Neumann (France), Manuel Rodrigues (France) & Robert Verdijk (The Netherlands)

04:00 p.m. - 04:08 p.m.

Combining Checkpoint Inhibitors and liver perfusion

Presenter: Thais Tong (The Netherlands)

04:08 p.m. - 04:16 p.m.

PERIO-01: A phase 1/1b trial of hepatic arterial infusion of SD-101 +/- checkpoint inhibition in metastatic uveal melanoma using pressure-enabled drug delivery

Presenter: Sapna Patel (United States)

04:16 p.m. - 04:24 p.m.

Macrophage Inhibitory Factor (MIF) Inhibition as a novel adjuvant treatment strategy for high risk uveal melanoma (UM)

Presenter: Alex Rai (United States)

04:24 p.m. - 04:32 p.m.

Predominance of CD8+ T cell infiltration is most pronounced in high-risk primary uveal melanoma

Presenter: Kalijn Bol (The Netherlands)

04:32 p.m. - 04:40 p.m.

MBD4 deficiency is predictive of response to immune checkpoint inhibitors in metastatic uveal melanoma patients

Presenter: Manuel Rodrigues (France)

04:40 p.m. - 04:48 p.m.

Tebentafusp in UM

Presenter: Sophie Piperno-Neumann (France)

04:48 p.m. - 04:56 p.m.

Metastatic uveal melanoma patients with long term survival after tebentafusp

Presenter: Marlana Orloff (United States)

EURbG Business Meeting

04:00 p.m. - 05:00 p.m.

Willem van de Velde

EURbG Business Meeting (parallel session, members only)

05:00 p.m. - 07:00 p.m.

Golden Dome Building - LUMC Building 3

Welcome Reception

Program

Program at a glance

Information

Organizing Secretariat